Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A

Journal of Surgical Oncology

Volumn 64, Issue 3, 1997, Pages 222-230

  Juhl, Hartmut ^a,b   Helmig, Frank ^a   Baltzer, Katrin ^a   Kalthoff, Holger ^a   Henne Bruns, Doris ^a   Kremer, Bernd ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

adjuvant therapy; complement resistance; gastrointestinal cancer; monoclonal antibodies

Indexed keywords

ANAPHYLATOXIN; ANTIBODY CONJUGATE; CD59 ANTIGEN; COBROTOXIN; DECAY ACCELERATING FACTOR; EDRECOLOMAB; MEMBRANE COFACTOR PROTEIN;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CHROMIUM 51 RELEASE; COLON CANCER; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT HEMOLYSIS TEST; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; STOMACH CANCER;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD46; ANTIGENS, CD55; ANTIGENS, CD59; COBRA VENOMS; COLONIC NEOPLASMS; COMPLEMENT ACTIVATION; COMPLEMENT C3A; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOTOXINS; MEMBRANE GLYCOPROTEINS; PANCREATIC NEOPLASMS; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0030904597     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199703)64:3<222::AID-JSO9>3.0.CO;2-C     Document Type: Article

References (42)

1. Roder J, Böttcher K, Siewert JR, et al.: Prognostic factors in gastric carcinoma. Cancer 1993; 72:2089-2097.
2. Gall FP, Hermanek P: Wandel und derzeitiger Stand der chirurgischen Behandlung des colorectalen Carcinoms. Chirurg 1992; 63:227-234.
3. Manabe T, Ohshio G, Baba N, Miyashita T, et al.: Radical pancreatectomy for ductal cell carcinoma of the head of the pancreas. Cancer 1989; 64:1132-1137.
4. Moertel C, Fleming T, McDonald J, et al.: Levamisole and fluoruracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322:352-358.
5. Steele G: Adjuvant therapy for patients with colorectal cancer. World J Surg 1995; 19:241-245.
6. Douglass H: Adjuvant therapy for pancreatic cancer. World J Surg 1995; 19:270-274.
7. McDonald J, Schnall S: Adjuvant treatment of gastric cancer. World J Surg 1995; 19:221-225.
8. Köhler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495-449.
9. Dillman RO: Antibody therapy. In Oldham RK (ed): "Principles of Cancer Biotherapy." 1990; 395-433.
10. Göttlinger HG, Funke I, Johnson JP, et al.: The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumour therapy: Its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer 1986; 38:47-53.
11. Sears H, Herlyn D, Steplewski Z, Koprowski H: Phase-II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res 1985; 45:5910-5913.
12. Bosslet K, Keweloh H-C, Hermentin P, et al.: Percolation and binding of monoclonal antibody BW494 to pancreatic carcinoma tissues during high dose immunotherapy and consequences for future therapy modalities. Br J Cancer 1990; 62:37-39.
13. Jain RK: Delivery of novel therapeutic agents in tumors: Physiological barriers and strategies. J Natl Cancer Inst 1989; 81:570-576.
14. Kunkel S, Ward P, Caporale L, Vogel C-W: The complement system. In Bellanti J (ed): "Immunology III." Philadelphia: WB Saunders. 1985; p 106-116.
15. Richard S, Farrell C, Shaw A, et al.: C5a as a model for chemotactic factor-stimulated tyrosine phophorylation in the human neutrophil. J Immunol 1994; 152:2479-2487.
16. Kojima A, Iwata K, Seya T, et al.: Membrane cofactor protein (CD46) protects cells predominantly from alternative complement pathway-mediated C3-fragment deposition and cytolysis. J Immunol 1993; 151:1519-1527.
17. Nicholson-Weller A, Wang C: Structure and function of decay accelerating factor CD55. J Lab Clin Med 1994; 123:485-491.
18. Morgan BP, Meri S: Membrane proteins that protect against complement lysis. Springer Semin Immunopathol 1994; 15:369-396.
19. Cheung N-KV, Walter EI, Smith-Mensah WH, et al.: Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J Clin Invest 1988; 81:1122-1128.
20. Vogel C-W: Cobra venom factor: the complement-activating protein of cobra venom. In Tu AT(ed): "Handbook of Natural Toxins." New York: Marcel Dekker 1991; 147-188.
21. Herlyn M, Steplewski Z, Herlyn D, Koprowski H: Colorectal carcinoma-specific antigen: Detection by means of monoclonal antibodies. Proc Natl Acad Sci 1979; 76:1438-1442.
22. Sekiguchi M, Sakakibara K, Fujii G: Establishment of cultured cell lines derived from a human gastric carcinoma. Jpn J Exp Med 1978; 48:61-68.
23. Fogh J, Fogh JM, Orfeo T: One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 1977; 59:221-226.
24. Leibovitz A, Stinson JC, McCombs WB, et al.: Classification of human colorectal adenocarcinoma cell lines. Cancer Res 1976; 36:4562-4569.
25. Morgan RT, Woods LK, Moore GE, et al.: Human cell line (COLO357) of metastatic pancreatic adenocarcinoma. Int J Cancer 1980; 25:591-598.
26. Petrella EC, Wilkie SD, Smith CA, et al.: Antibody conjugates with cobra venom factor. Synthesis and biochemical characterization. J Immunol Meth 1987; 104:159-172.
27. Vogel C-W, Müller-Eberhard HJ: Induction of immune cytolysis: tumor cell killing by complement is initiated by covalent complex of monoclonal antibody and stable C3/C5 convertase. Proc Natl Acad Sci USA 1981; 78:7707-7711.
28. 99mTc-anti-CEA antibody by a two step approach. Cancer Res 55 1995; Suppl:5749s-5755s.
29. Lowe SW: Cancer therapy and p53. Current Opinion Oncol 1995; 7:547-553.
30. Juhl H, Stritzel M, Wroblewski A, et al.: Immunocytological detection of micrometastatic cells: comparative evaluation of findings in the peritoneal cavity and the bone marrow of gastric, colorectal and pancreatic cancer patients. Int J Cancer 1994; 57:330-335.
31. Pantel K, Schlimok G, Braun S, et al.: Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993; 85:1419-1424.
32. Riethmüller G, Schneider-Gädicke E, Schlimok G, et al.: Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 1994; 343:1177-1183.
33. Juhl H, Petrella EC, Cheung N-KV, et al.: Additive cytotoxicity of different monoclonal antibody cobra-venom factor conjugates for human neuroblastoma cells. Immunobiol 1997 (in press).
34. Sakuma T, Kodama K, Hara T, et al.: Levels of complement regulatory molecules in lung cancer: Disappearance of the D17 epitope of CD55 in small-cell carcinoma. Jpn J Cancer Res 1993; 84:753-759.
35. Koretz K, Brüderlein S, Henne C, Möller P: Decay-accelerating factor (DAF, CD55) in normal colorectal mucosa, adenomas and carcinomas. Br J Cancer 1992; 66:810-814.
36. Müller B, Müller-Ruchholtz W: Covalent conjugates of monoclonal antibody and cobra venom factor mediate specific cytotoxicity via alternative pathway of human complement activation. Leukemia Res 1986; 11:461-468.
37. 2-CVF conjugate are equally cytotoxic. Molec Immunol 1990; 27:957-964.
38. Leventhal JR, Dalmasso AP, Cromwell JW, et al.: Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 1993; 55:857-866.
39. Regal JF, Fraser DG, Anderson DE, Solem LE: Enhancement of antigen-induced bronchoconstriction after intravascular complement activation with cobra venom factor. J Immunol 1993; 150:3496-3505.
40. Schlottmann K, Gulbins E, Rauterberg EW, Steinhausen M: Effects of systemic complement activation on renal circulation of rats. Eur J Clin Invest 1994; 24:320-330.
41. Losman MJ, DeJager RL, Monestier M, et al.: Human immune response to anti-carcinoembryonic antigen murine monoclonal antibodies. Cancer Res 50 1990; Suppl:1055s-1058s.
42. Velders M, Litvinov S, Warnaar S, et al.: New chimeric anti-pancarcinoma monoclonal antibody with superior cytotoxicity-mediating potency. Cancer Res 1994; 54:1753-1759.